Role of Transforming Growth Factor Beta in Peripheral Nerve Regeneration: Cellular and Molecular Mechanisms

Peripheral nerve injury (PNI) is one of the most common concerns in trauma patients. Despite significant advances in repair surgeries, the outcome can still be unsatisfactory, resulting in morbidities such as loss of sensory or motor function and reduced quality of life. This highlights the need for...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neuroscience Vol. 16; p. 917587
Main Authors Ye, Zhiqian, Wei, Junbin, Zhan, Chaoning, Hou, Jin
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 13.06.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Peripheral nerve injury (PNI) is one of the most common concerns in trauma patients. Despite significant advances in repair surgeries, the outcome can still be unsatisfactory, resulting in morbidities such as loss of sensory or motor function and reduced quality of life. This highlights the need for more supportive strategies for nerve regrowth and adequate recovery. Multifunctional cytokine transforming growth factor-β (TGF-β) is essential for the development of the nervous system and is known for its neuroprotective functions. Accumulating evidence indicates its involvement in multiple cellular and molecular responses that are critical to peripheral nerve repair. Following PNI, TGF-β is released at the site of injury where it can initiate a series of phenotypic changes in Schwann cells (SCs), modulate immune cells, activate neuronal intrinsic growth capacity, and regulate blood nerve barrier (BNB) permeability, thus enhancing the regeneration of the nerves. Notably, TGF-β has already been applied experimentally in the treatment of PNI. These treatments with encouraging outcomes further demonstrate its regeneration-promoting capacity. Herein, we review the possible roles of TGF-β in peripheral nerve regeneration and discuss the underlying mechanisms, thus providing new cues for better treatment of PNI.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Ken Kadoya, Hokkaido University, Japan; Anand Krishnan, University of Saskatchewan, Canada
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience
Edited by: Hong-Bin Lu, Central South University, China
These authors have contributed equally to this work and share first authorship
ISSN:1662-453X
1662-4548
1662-453X
DOI:10.3389/fnins.2022.917587